Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NVCR - NovoCure Ltd


IEX Last Trade
19.44
-0.310   -1.595%

Share volume: 1,141,770
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Surgical and Medical Instrument Manufacturing : -0.56%

PREVIOUS CLOSE
CHG
CHG%

$19.75
-0.31
-1.57%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
27%
Profitability 25%
Dept financing 26%
Liquidity 75%
Performance 19%
Company vs Stock growth
vs
Performance
5 Days
7.88%
1 Month
-16.73%
3 Months
-12.71%
6 Months
21.35%
1 Year
-11.35%
2 Year
-76.01%
Key data
Stock price
$19.44
P/E Ratio 
-12.47
DAY RANGE
N/A - $20.22
EPS 
-$1.57
52 WEEK RANGE
$10.87 - $24.74
52 WEEK CHANGE
-$0.13
MARKET CAP 
2.104 B
YIELD 
N/A
SHARES OUTSTANDING 
108.217 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/24/2024
BETA 
1.75
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$807,699
AVERAGE 30 VOLUME 
$943,975
Company detail
CEO: Asaf Danziger
Region: US
Website: https://www.novocure.com/
Employees: 1,224
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.

Recent news